Safety, Tolerability, and EEG-Based Target Engagement of STP1 (PDE3,4 Inhibitor and NKCC1 Antagonist) in a Randomized Clinical Trial in a Subgroup of Patients with ASD.
Erickson CA, Perez-Cano L, Pedapati EV, Painbeni E, Bonfils G, Schmitt LM, Sachs H, Nelson M, De Stefano L, Westerkamp G, de Souza ALS, Pohl O, Laufer O, Issachar G, Blaettler T, Hyvelin JM, Durham LA.
Erickson CA, et al. Among authors: bonfils g.
Biomedicines. 2024 Jun 27;12(7):1430. doi: 10.3390/biomedicines12071430.
Biomedicines. 2024.
PMID: 39062003
Free PMC article.